RxNews®

June 24, 2026 - The FDA announced the approval of Pfizer’s Ibrance (palbociclib) tablets or capsules, in combination with trastuzumab, with or without Perjeta® (pertuzumab), and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer following induction treatment.

June 26, 2026 - AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older.

June 24, 2026 - The FDA announced the approval of Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy), for two new indications 1) As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy; 2) In combination with Keytruda® (pembrolizumab) or Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-authorized test.

June 26, 2026 - Merz Therapeutics announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment of upper limb spasticity in patients 2 years of age and older.

June 26, 2026 - Viridian Therapeutics announced the FDA approval of Lumvoa (veligrotug-vvze), for the treatment of thyroid eye disease (TED) regardless of thyroid eye disease activity or duration.